Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Keytruda+Chemo neoadjuvant in early ER+/HER2- breast cancer

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 24, 2023 10:03am

104 Views

Post# 35698028

RE:RE:Keytruda+Chemo neoadjuvant in early ER+/HER2- breast cancer

Second-line (2L) therapy for hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer is yet to be established.

ONCYs pelareorep 2L combination therapy would be the first.

<< Previous

Bullboard Posts

Next >>

Gold, growth and sustainability in focus for Mandalay Resources